Insider Selling: GoodRx (NASDAQ:GDRX) Major Shareholder Sells $437,819.12 in Stock

GoodRx Holdings, Inc. (NASDAQ:GDRX) major shareholder Francisco Partners Iv, L.P. sold 127,273 shares of GoodRx stock in a transaction that occurred on Tuesday, August 25th. The shares were sold at an average price of $3.44, for a total transaction of $437,819.12. Following the transaction, the insider directly owned 643,466 shares in the company, valued at $2,213,523.04. This represents a 16.51% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Major shareholders that own 10% or more of a company’s shares are required to disclose their transactions with the SEC.

Francisco Partners Iv, L.P. also recently made the following trade(s):

• On Wednesday, August 26th, Francisco Partners Iv, L.P. sold 1,296,177 shares of GoodRx stock. The stock was sold at an average price of $3.50, for a total transaction of $4,536,619.50.
• On Monday, August 24th, Francisco Partners Iv, L.P. sold 143,594 shares of GoodRx stock. The shares were sold at an average price of $3.46, for a total transaction of $496,835.24.
• On Friday, August 21st, Francisco Partners Iv, L.P. sold 274,717 shares of GoodRx stock. The shares were sold at an average price of $3.50, for a total transaction of $961,509.50.
• On Thursday, August 20th, Francisco Partners Iv, L.P. sold 447,259 shares of GoodRx stock. The shares were sold at an average price of $3.52, for a total transaction of $1,574,351.68.
• On Wednesday, August 19th, Francisco Partners Iv, L.P. sold 471,975 shares of GoodRx stock. The stock was sold at an average price of $3.53, for a total transaction of $1,666,071.75.

GoodRx Trading Up 0.6%

Shares of GDRX stock opened at $3.53 on Friday. GoodRx Holdings, Inc. has a 52-week low of $1.77 and a 52-week high of $5.81. The company has a debt-to-equity ratio of 0.74, a quick ratio of 1.38 and a current ratio of 1.38. The firm has a market capitalization of $1.21 billion, a PE ratio of 88.27, a PEG ratio of 1.75 and a beta of 1.60. The stock has a fifty day simple moving average of $3.21 and a two-hundred day simple moving average of $2.67.

GoodRx (NASDAQ:GDRX) last posted its quarterly earnings results on Wednesday, August 5th. The company reported $0.08 EPS for the quarter, meeting analysts’ consensus estimates of $0.08. GoodRx had a return on equity of 7.22% and a net margin of 2.07%.The business had revenue of $200.41 million for the quarter, compared to analysts’ expectations of $193.23 million. During the same period last year, the firm earned $0.09 earnings per share. The business’s quarterly revenue was down 1.3% on a year-over-year basis. On average, analysts predict that GoodRx Holdings, Inc. will post 0.16 EPS for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the company. Prescott Group Capital Management L.L.C. purchased a new position in shares of GoodRx in the fourth quarter valued at $4,812,000. Technology Crossover Management X Ltd. purchased a new stake in GoodRx during the second quarter valued at $4,762,000. Northwestern Mutual Wealth Management Co. lifted its position in GoodRx by 10,242.5% during the fourth quarter. Northwestern Mutual Wealth Management Co. now owns 1,502,666 shares of the company’s stock valued at $4,072,000 after purchasing an additional 1,488,137 shares during the last quarter. California State Teachers Retirement System grew its stake in shares of GoodRx by 192.6% in the 2nd quarter. California State Teachers Retirement System now owns 1,684,431 shares of the company’s stock worth $4,851,000 after buying an additional 1,108,766 shares in the last quarter. Finally, AQR Capital Management LLC grew its stake in shares of GoodRx by 188.0% in the 4th quarter. AQR Capital Management LLC now owns 1,158,546 shares of the company’s stock worth $3,140,000 after buying an additional 756,209 shares in the last quarter. 63.77% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

GDRX has been the topic of several recent analyst reports. Wells Fargo & Company lifted their target price on GoodRx from $3.50 to $5.00 and gave the company an “overweight” rating in a research note on Friday, August 7th. UBS Group increased their price objective on shares of GoodRx from $2.50 to $3.75 and gave the company a “neutral” rating in a report on Thursday, August 13th. Citigroup increased their price objective on shares of GoodRx from $4.00 to $5.00 and gave the company a “buy” rating in a report on Tuesday, August 11th. Wall Street Zen upgraded shares of GoodRx from a “hold” rating to a “buy” rating in a research report on Saturday, August 15th. Finally, The Goldman Sachs Group reissued a “neutral” rating and issued a $4.00 target price on shares of GoodRx in a report on Friday, August 7th. Four analysts have rated the stock with a Buy rating, six have assigned a Hold rating and three have assigned a Sell rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $4.23.

About GoodRx

GoodRx Holdings, Inc (NASDAQ: GDRX) operates a digital healthcare platform designed to help consumers compare prescription drug prices at retail pharmacies across the United States. Through its website and mobile applications, GoodRx aggregates pricing and discount information from a wide network of pharmacies, enabling users to access coupons and savings programs on both generic and brand-name medications. The platform also features price transparency tools that inform patients about cost variations and available discounts to alleviate the financial burden of prescription medications.

In addition to its core drug pricing service, GoodRx offers telehealth services under the GoodRx Care brand, providing virtual consultations for a range of non-emergency conditions and prescription needs.